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Abstract 
 
Candidiasis is a serious disease caused by Candida albicans that affects over four billion 
people a year. Of those infected, 32,000 of them develop systemic infections in the US with a 
30%-60% fatality rate. This type of infection is especially prevalent in immune-compromised 
individuals such as HIV-infected, diabetes and cancer patients. In this study, we mutagenized 
Caenorhabditis elegans and exposed them to C. albicans in order to isolate mutants resistant to 
the yeast infection. After survival tests of mutant C. elegans on C. albicans-containing media, 
three putative resistant strains were isolated for future analysis. Further characterization of these 
mutants may identify genes required for sensitivity to C. albicans infections and be useful in the 
study and prevention of Candidiasis. 
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1. Introduction 
 
Candidiasis is a yeast infection cause by Candida albicans. It is a serious disease that 
affects over four billion people a year worldwide.1 In the United States, 32,000 individuals are 
infected with the systemic infection of C. albicans each year.2 Most Candida infections occur on 
epithelial surfaces such as in the mouth, nail, vaginal, and skin regions. These surface infections 
are easily treatable using topical or oral anti-fungal agents.1 In some cases, the Candida infection 
passes into the blood stream, becomes systemic and infects many vital organs. This systemic 
infection is commonly seen in patients that have compromised immune systems such as those 
with HIV, diabetes, cancer, or those who are recovering from an organ transplant or other major 
surgeries. Systemic Candidiasis is fatal with a 30%-60% mortality rate.3  
Over the past decade the seriousness of Candida infections has increased, causing a 
necessity for a suitable treatment to battle these infections. Little is known about the effects that 
Candidiasis has on the body. It has been the interest of many different research organizations to 
create a model of what occurs in the infected body. By using the organism Caenorhabditis 
elegans as a model host, information about this disease can be discovered.  
Our research sought to induce a mutation in C. elegans, a model organism, that might 
cause a resistance to infection by C. albicans. If resistant mutants are successfully isolated, the 
mutation can be identified to determine the mutated gene that is responsible for causing this 
resistance. The identified gene can then be compared to homologous genes in humans to help 
create a better understanding of the Candidiasis infection. By investigating the genes that could 
be responsible for resistance to Candida infections, an effective treatment for the systemic 
infections of Candidiasis could be created to help lower the mortality rate.  
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2. Background 
2.1 Candida albicans Background and Infections 
Candida albicans is the most common human fungal pathogen and is naturally found in 
healthy human digestive and reproductive organs. It can exist in two forms – as either small 
circular cocci yeast cells or branch-like hyphae cells. 
 
 
Figure 1: Two Forms of the Candida albicans Yeast4 
The small cocci yeast cells, shown in the left panel of Figure 1, are often seen on the 
mucosal membranes in the body while the branch-like hyphae, shown in the right panel of Figure 
1, are commonly seen in liquid cultures in vitro. Both shapes help C. albicans establish 
bloodstream infections. The small cocci yeast cells are ideal for passing through the epithelial 
membrane to reach the blood stream. Once in the blood stream, the yeast begins to form hyphae, 
which disrupts surrounding tissues, thus causing the harmful effects on many organs that are 
seen in systemic Candidiasis.5  
 
2.1.1 Topical Infections of Candida albicans 
C. albicans prefers the presence of moist areas of the body, which is why it is usually 
found in the genital and oral regions. Many other microorganisms grow in healthy mucus 
membranes in the body. However, when other organisms become depleted, the yeasts are able to 
out compete for the limited resources. When the yeast takes over in the mouth or throat, it is 
often called ‘thrush’ and causes a sore throat along with a white coating in the mouth, as seen in 
Figure 2 below.6 When the infection is in the female genital regions, it is called vulvovaginitis 
and can cause extreme itching and burning sensations along with possible white discharge.2  
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Figure 2: Oral "Thrush" Infection of Candida albicans7 
In normal healthy individuals, these infections are quickly resolved with the use of 
topical and oral anti-fungal agents. However, these treatments are ineffective once the infection 
enters the blood stream as seen in systemic Candidiasis patients.  
 
2.1.2 Systemic Candidiasis 
Of all of the systemic Candidiasis infections that occur, 90% of them are caused by the C. 
albicans yeast, making it the fourth most common blood stream infection in hospitalized patients 
in the United States.2,3 Thrush or vulvovaginitis infections rarely becomes a systemic Candidiasis 
infection unless the patient has the necessary risk factors that affect the body’s ability to fight off 
infections. These include patients with compromised immune systems, physical trauma, poor 
nutrition, or previous treatment with steroids or antibiotics. Once the infection has reached the 
blood stream, diagnosis can be difficult due to a wide range of symptoms. The main symptoms 
are fever and chills, which are normally associated with a bacterial infection. This sometimes 
causes misdiagnosis and mistreatment. The rest of the symptoms vary depending on the organs 
that have become infected.2 Candidiasis is normally diagnosed though blood cultures that look 
for the presence of yeast. The C. albicans that is normally seen in the blood culture is the hyphal 
form, which disrupts the surrounding tissues of vital organs. 
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Figure 3: Histopathology of the Tongue and Esophagi of Mice infected with Active C. albicans 
and Null Heat Killed C. albicans Strains8 
 Figure 3 shows the tongue (A&B) and esophagi tissues (C&D) infected with active C. 
albicans (A&C) and a null heat killed C. albicans (B&D). The tissues that were infected with the 
active yeast showed a greater inflammatory reaction, seen by the increased amount of black 
spotting, demonstrating how organs react when infected with Candidiasis. Although panel B 
shows black spots, it is significantly less than panel A, illustrating the difference between active 
and heat killed C. albicans.8 Organs can also form abscesses and invasions in the organ walls or 
even cell death from the presence of the cocci yeast cells alone.5,9 Candidiasis is difficult to treat 
due to the widespread infection of various tissues and organs. Also, many treatments for mucosal 
infections are applied directly to the area of infection.  For these reasons, antifungal agents that 
are currently used to treat common mucosal infections are often ineffective when attempting to 
treat systemic Candidiasis. The 30%-60% fatality rate of systemic Candidiasis infections is a 
great concern to the medical community and has helped to fuel the search for a treatment for 
Candidiasis.3  
 
2.1.3 Recent Interest in Candidiasis 
Once only considered the cause of aggravating but not dangerous mucosal infections, 
Candida has recently garnered much more attention due to its potential to cause life threatening 
systemic infections. Additionally, C. albicans has become a common issue in hospitals, 
especially in intensive care units where close quarters allow for pathogens to spread rapidly.10  
Fungal infections have always been difficult to treat, especially in patients with weakened 
or compromised immune systems. Firstly, they show non-specific symptoms, causing difficulties 
in diagnosing the disease. Effective treatments are complicated by the increase of anti-fungal 
resistant infections and the need for medications that will not harm the body in the process. 
When a treatment is administered, it does not always kill the yeast and could lead to later 
relapses of the disease.11 Finding new anti-fungal medications has become a major interest to the 
scientific community. 
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2.2 Caenorhabditis elegans Background  
Caenorhabditis elegans are non-parasitic nematodes that are naturally present in the soil 
around the world. Adult hermaphrodites are approximately 1 mm in length, making them easy to 
observe with a simple stereo dissecting microscope. In addition, the nematodes are transparent, 
allowing the details of cell division, as well as physiological and reproductive process to be 
observed in vivo (Figure 4). C. elegans are easily cultured in the laboratory and have been the 
subject of countless research investigations; examples include analysis of the structure and 
function of the complete nervous system.12 Thus, these simple worms have become an 
exceedingly popular experimental model due to their simple genetic makeup, small size, ease of 
maintenance, and their ability to be stored cryogenically.13 
 
Figure 4: Caenorhabditis elegans Adult Hermaphrodite14 
The popularity of C. elegans as a laboratory model organism started in 1963 with Sydney 
Brenner, who was interested in finding a simple organism with which to investigate animal 
development.12 Previously Drosophila were used to study genetic patterns; however, the full 
genome of the fly was not available. Therefore, a new test organism was sought out. C. elegans 
were chosen due to their simplicity and rapid growth cycle. Its simplicity has allowed researchers 
to sequence the C. elegans genome in its entirety, which contains around 100 million base pairs 
on six chromosomes with an estimated 20,000 genes.15,16 This makes the C. elegans genome 
much smaller than the human genome, which contains around 3 billion base pairs on 23 
chromosomes with an estimated 30,000 genes.15,17 C. elegans can be grown in the lab on agar-
filled petri dishes where they feed on Escherichia coli bacteria. If a specific worm is desired, 
they are able to be removed from the plates individually by a process called ‘picking’.  
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The ability to freeze and thaw worms in a cryostasis cycle, developed by John Sulston in 
1969, allows a large number of wild type (N2) and mutant worm strains to exist in a stock center 
where specific mutants can be requested.18 The L1 stage survives cryostorage better than other 
developmental stages After the desired period of storage time, the worms can be thawed and 
allowed to resume development.13  
 
2.2.1 Anatomy of Caenorhabditis elegans 
C. elegans consist of an unsegmented cylindrical body with tapered ends. Some of the 
organ systems that will be discussed are shown in Figure 5. Starting from the outside in, the 
worm is surrounded by a cuticle that is secreted by the epithelial cells (hypodermal stem cells) 
that reside directly below it. The cuticle surrounds the worm to maintain its shape and protects 
the worm from environmental conditions. The excretory, nerve and muscle systems all reside 
below the epithelial cells. The excretory system removes fluid from the worm through a 
combination of pore, duct, canal and gland cells. This process excretes fluid to help maintain the 
worm’s salt balance. The worm’s nerve and muscle systems work together through a process of 
signals sent by the nerves to the muscles that contract to help move the worm though its 
environment.13  
 
 
Figure 5: Anatomy of Caenorhabditis elegans19 
Separating these organs from the inner organs is a pseudocoelomic cavity, which is a 
fluid filled space that helps to separate the organs in the worm, mainly the alimentary and 
reproductive systems. The alimentary system brings nutrients though a two-lobed pharynx and 
passes ingested food into the intestine; digestive wastes exit by defecation through the anal 
opening.13 The reproductive system varies depending on the gender of the worms, consisting of a 
male gonad in males and the addition of a female gonad, which produces eggs, in 
hermaphrodites. 
For the most part, C. elegans are hermaphrodites and are able to self-fertilize and pass on 
exact copies of their genes to their offspring. Since one homozygous worm will quickly produce 
hundreds of exact genetic copies of itself, the worms are very useful in experiments involving 
genetic mutations. However, a few male worms arise though infrequent spontaneity (0.1%) in the 
hermaphrodite germ-lines, and when a male and hermaphrodite mate, the male germ-line arises 
about 50% of the time.20 The male development is due to a spontaneous X chromosome 
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nondisjunction – hermaphrodites are (XX) and males are (XO).13 The physical differences can be 
seen in Figure 6, comparing the sperm-containing gonads of the male worms with the 
hermaphrodite gonads that contains both egg and sperm. Additional differences visible in Figure 
6 are the embryos that are contained in the body of the hermaphroditic worm and the hook-like 
tail contained at the end of the male worm. 
 
 
Figure 6: Differences between Male (A) and Hermaphrodite (B) Caenorhabditis elegans21 
For males to fertilize hermaphrodite eggs, they use their tail, which houses the ‘fan’ and 
aids the male worm in hooking onto the hermaphroditic worm to position itself and fertilize the 
eggs. In the hermaphrodites, the eggs are simply fertilized by the gonad containing sperm located 
next to the eggs. Once the eggs are fertilized, either though self-fertilization or mating, the wild-
type hermaphrodite is able to lay about 300 eggs.13  
 
2.2.2 Lifecycle of Caenorhabditis elegans 
The worm life cycle has a generation time of 3 days at 20°C and falls into 6 stages. These 
stages are embryos, first stage larva (L1), L2, L3, L4, and adult, which can be seen in Figure 7 
below.12 The four larval stages are separated from each other and from the adult by the process 
of molting and synthesizing new cuticles at each stage. Each cuticle has a different physical and 
chemical structure from the one before. An additional option for the worms is to enter into the 
dauer larval stage when there are unfavorable conditions such as lack of food or decrease in 
temperature. This stage allows the worms to be dormant for long periods of time.13  
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Figure 7: Life Cycle of Caenorhabditis elegans13 
The size of the worms is used to roughly distinguish the stages. However, the only clear-
cut distinction visible in the dissecting microscope is the presence of the hermaphrodite vulva in 
adults. In Figure 8, the relative sizes of the different stages are shown in comparison to each 
other.  
 
 
Figure 8: Relative Sizes of the Different Stages of Caenorhabditis elegans Development13 
The different sizes of these varying stages provide a rough guide to identify the 
appropriate stages to use for specific experiments.  
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2.2.3 Candida albicans Effect on Caenorhabditis elegans 
C. elegans have been used as a model for this infectious pathogen due to the way that C. 
elegans are able to model key aspects of the mammalian pathogenesis. It has already been 
determined by many researchers including that C. albicans have a negative effect on the health 
of C. elegans when exposed. Figure 9 shows the survival rate of C. elegans when exposed to 
heat-killed (HK) E. coli and C. albicans in relation to live C. albicans over a span of 150 hours 
in an experiment performed by Pukkila-Worley et al. From the graph, it is seen that 100% of the 
worms survived in the presence of the heat-killed E. coli and C. albicans, while less than 20% 
survived in the presence of the live C. albicans.22 This demonstrates that it is the presence of live 
C. albicans that causes the disease and not just the presence of the yeast cells alone.  
 
Figure 9: Survival Rate of Caenorhabditis elegans Exposed to Candida albicans22 
The physical effects of the live C. albicans versus the heat-killed C. albicans are shown 
in Figure 10 below. After 16 hours at 25°C, the heat-killed E. coli showed no distention or 
expansion of the intestine in the proximal (left) or distal (right) sections of the worm body. The 
lumen or outer edge of the intestine is marked with the black arrows. HK C. albicans showed 
slight distention of the intestine from the collection of a small amount of the dead yeast. 
However, the live C. albicans yeasts caused a large distention of the intestine, illustrating the 
harmful effects the yeast can have on the worms.22  
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Figure 10: Images of Caenorhabditis elegans Exposed to Heat-Killed E. coli, Heat-Killed Candida albicans, 
and Live Candida albicans22 
Similar to the pathology of the yeast infection in humans, once the C. albicans is in the 
intestine of the C. elegans the yeast converts into its hyphal form, usually seen in liquid media 
cultures, and fatally destroys the surrounding tissues as shown in Figure 11.  
 
 
Figure 11: Candida albicans Hyphae Protruding from a Caenorhabditis elegans23 
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2.3 Mutations Overview 
Mutations are changes to the genome of an organism. These are normally caused at low 
frequencies by spontaneous errors in DNA replication. The frequency of mutation is increased by 
mutagens, which include environmental and chemical agents such as ionizing radiation, 
ultraviolet light, nitrous acid and many other natural and artificial chemicals. Induced mutations 
can include changes not only to the nucleotide sequence, but also the structure and function of 
the DNA such as the creation of pyrimidine dimers and hydroxyl radicals. In chemical 
mutagenesis, there are generally two major types of DNA alterations: point mutations and 
insertion/deletion mutations. In point mutations, a single base pair is replaced with another 
different base pair. In this category, there are two subclasses: transitions, where one type of 
nucleotide (purines or pyrimidines) is replaced by a nucleotide from the same class, and 
transversions, where one type of nucleotide is replaced by another nucleotide from a different 
class. With insertion/deletion mutations, one or more base pairs are either removed or added to 
the DNA, both resulting in the disruption of the DNA sequence.24  
These changes, when found in the coding sequence of a gene, may then affect the 
translated protein sequence, showing the results of missense, nonsense, silent, or frame-shift 
mutations. Missense mutations occur when a mutation in the codon for the protein results in the 
change of the original amino acid into another amino acid. Nonsense mutations cause the codon 
that was originally coded for an amino acid to now code for a stop codon and terminate the 
protein sequence prematurely. Silent mutations are mutations that have no effect on the protein 
sequence. Frame-shift mutations occur from an insertion or deletion of a nucleotide where the 
entire sequence is shifted over, resulting in an almost entirely different protein sequence.24 
Finally, insertions and deletions can also delete portions of a protein-coding sequence or insert 
unrelated sequences, resulting in alterations of a whole section of a protein. 
In this research, the desired mutations are point mutations, where one of the bases in the 
DNA is changed to another base pair. This single mutation can cause a change in the amino acid 
that it codes and, as seen in the example in Figure 12, can have a significant effect like causing 
normal hemoglobin to become sickle-cell hemoglobin. A frame-shift mutation in the same gene 
would likely to cause a complete absence of hemoglobin instead of just a function change. 
 
 
Figure 12: Example of Point Mutations in Normal versus Sickle-Cell Hemoglobins25 
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Mutations can occur in any type of cells, either somatic (normal cells) or germ-line 
(reproductive) cells. Only changes to germ-line cells can be heritable and passed down from 
parent to offspring while mutations in somatic cells only affect the individual.24 The geneticist is 
primarily interested in heritable mutations, which can be maintained in mutant stocks for the 
study of mutant phenotypes and identification of the mutated genes. 
 
2.3.1 Mutagens used on Caenorhabditis elegans 
When introducing mutations into C. elegans or any organism, the goal is to create 
mutations in the genome of the germ-line cells that will eventually be passed on to its progeny. 
This creates the ability to test the progeny for both the retention of the mutations and its effects 
on normal functions. Mutagenesis of the C. elegans is focused on N2 L4 worms that are in the 
process of becoming adults and are forming germ line cells inside the gonad lumen. The germ 
line cells will be actively dividing and multiplying mitotically, and will easily be affected by the 
chemicals creating the mutations. The resulting first generation progeny (F1) will contain 
mutations that were generated independently of each other and in effect, are different from each 
other even though they came from the same parent C. elegans. In the F1 generation, mutations 
will be present in heterozygotes. However, by self-fertilization of such F1 hermaphrodites, the 
F2 will include an average of ¼ homozygous individuals for each F1 carrying a mutation. Thus, 
hermaphrodite reproduction allows homozygous mutation to be easily obtained. 
One the most common chemicals used for mutagenesis of C. elegans is ethyl 
methanesulfonate (EMS). EMS is an alkylating agent that induces point mutations by chemically 
modifying the nucleotide guanine (G) to form O6-ethylguanine that would later base pair with 
thymine (T) and not with cytosine (C). After subsequent DNA repair and division, the original 
G/C pair would then be substituted into an A/T pair.26 What makes EMS such a popular 
chemical to use for mutagenesis is its ability to create mutations at high frequencies of 3x10-4 per 
gene per genome compared to 1x10-6 for spontaneous mutations, with relatively small amounts 
of the chemical and minimal toxicity to the rest of the organism.27 Along with the high 
mutability, EMS is also relatively inexpensive, easily storable, and can be safely neutralized 
inexpensively with salts such as sodium hydroxide (NaOH).  
Another chemical that is used for mutagenesis is N-ethyl-N-nitrosourea (ENU), which 
creates a greater chance of an A/T base pair being altered to a G/C base pair. However, the ENU 
mutagen is much more toxic to the worms than EMS. This creates the necessity to determine a 
balance between concentrations that are too toxic versus concentrations that are too low to 
induce mutations.27  
Even though the mutations can occur on any gene and in multiple locations, there are 
generally three types of second generation progeny (F2) that can result from the mutated first 
generation: F2 without any mutations on both homologs, F2 with mutations on only one of the 
homologs, or F2 with mutations on both homologs. Amongst the F2 progeny of an F1 
hermaphrodite carrying a mutation, the F2 will include 50% homozygous wild type and 25% 
each for the offspring with the homozygous or heterozygous mutations.   
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Although the F2s may all have different genotypes, the phenotypic differences between 
them may not be significantly noticeable. Therefore, they must be tested and screened to 
distinguish F2s with mutations and F2s without mutations. In our case, the screening of mutated 
C. elegans will consist of exposing the F2s to C. albicans for an extensive amount of time. Since 
C. albicans is toxic to the worms, the F2s that survive should include homozygous recessive 
mutants and homozygous or heterozygous dominant mutants.   
 
2.3.2 Screening for Mutated Caenorhabditis elegans 
In order to screen for resistance to infection by C. albicans, F2 progeny of mutated 
worms would be transferred onto a plate containing yeast and any that survive would be 
transferred back onto recovery E. coli plates. After initial screening, only one worm would be 
placed on each recovery plate to segregate mutant offspring. This allows for easier testing of one 
mutant strain at a time since hermaphrodite C. elegans self-fertilize. Surviving worms would 
later be transferred back onto yeast plates for a second screening, to ensure that they are in fact 
resistant to the infection and have retained that resistance throughout multiple generations. Once 
a successfully mutated C. elegans able to survive in the presence of C. albicans has been 
isolated, the mutant phenotype can be characterized, the mutation mapped to a region on a 
chromosome, and the gene identified by genome sequencing.   
 
2.4 Conclusion 
In this research, Caenorhabditis elegans were mutated with either EMS or ENU 
mutagens and exposed to Candida albicans to determine if any mutations are able to confer 
resistance to the fatal yeast infection. Clones of the mutated worms were then retested to confirm 
their resistant properties to the C. albicans infection before they were studied further. Over 40 
mutants were isolated and 13 putative resistant mutants were identified by additional survival 
screening. Investigation of what mutations cause these putative mutants to be resistant will allow 
us to further understand the mechanism of resistance to this yeast infection.  
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3. Materials and Methods 
 
The overall research procedures are summarized below. The details on how each material 
was made are described in Appendix A.  
 
3.1 Labeling and Naming of Caenorhabditis elegans 
All of the plates with worms were labeled using the following system. First was the 
mutation number or wild type (WT) name. The WT genome is referred to as N2, while the 
mutation batches are labeled as M1, M2, etc. Next is the strain number. If some worms from that 
mutation batch survived a test on the yeast plates and were recovered, they received their own 
strain number. The numbers follow as S1, S2, S3, etc. Next is the test number or the number of 
times that specific strain has been on yeast (T1, T2, T3, etc.), starting with T0 if they have not 
been exposed to yeast. Finally, the date on which the worms were plated on the plate was 
recorded to keep track of their life cycle. An example would be the first mutant found on 
mutation batch 2 would have the label M2S1 T1 since it was only exposed to the yeast once. 
 
3.2 Maintenance of Caenorhabditis elegans  
Three N2 C. elegans were placed onto a 60 mm x 15 mm E. coli spotted NG agar plate 
with a worm pick, which consisted of a platinum wire attached to the end of a glass Pasteur 
pipette, that allows individual worms to be picked up and transferred. The plates were then 
placed into a 22°C incubator and observed. The process was repeated once the E. coli spotting 
was close to being depleted or after multiple generations of the N2 C. elegans progeny (3-5 
days).  
 
3.3 Mutagenesis of Caenorhabditis elegans 
Mutagenesis was performed on worms from at least five NG agar plates, each containing 
around 300 unsynchronized L4 stage worms as well as a mixture of other developmental stages. 
The worms were washed off the media plates with M9 buffer and placed in a 15 mL conical 
tube. The tube was then placed into a centrifuge and spun at 2,000 x g relative centrifugal field 
(RCF) for 1 minute before the supernatant was removed and the resulting pellet of worms was 
rinsed with more M9. The centrifuge process was then repeated and the supernatant was 
removed. The total volume inside the tube was then brought up to 2 mL using M9. Once 20 µL 
of 50 mM mutagen (either the EMS or the ENU) was added, another 2 mL of M9 was added, 
giving a total volume of 4 mL of M9 in the tube. The tube was then placed on a nutator to rotate 
for 4 hours at 20ºC to allow for the even distribution of EMS or ENU with the C. elegans. 
Afterwards, the solution was centrifuged again, the supernatant removed, and the pellet rinsed 
with M9. This process was repeated 3-4 times. Once the worms were sufficiently washed to 
remove the mutagen, they were placed onto NG agar plates containing E. coli and placed in a 
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22ºC incubator to recover. Due to the toxicity and carcinogenicity of these chemicals great care 
was taken when working with EMS or ENU. All work was done in a hood while wearing gloves 
and protective eyewear. All liquids or materials that were in contact with the mutagen were 
properly neutralized and discarded. EMS solution was neutralized using NaOH pellets and the 
chemical left to degrade for 4 days, while ENU was degraded at room temperature over 24 hours. 
 
3.4 Testing Process for Caenorhabditis elegans 
Two to three days of recovery after mutagenesis occurred on E. coli plates, the worms 
were tested by transferring about 300 C. elegans Po’s plus F1’s  onto each 90 mm C. albicans, E. 
coli, and streptomycin spotted plates. The function of the E. coli was to provide the worms with 
some nutrition and the streptomycin prevents growth of bacterial contamination of the plates and 
the overgrowth of the E. coli. The worms were transferred to the yeast plates by washing the 
original plates with M9 buffer. All of the worms were transferred onto yeast plates regardless of 
generation and size. Plates containing N2 worms were also plated to act as a negative control to 
determine how long a non-resistant worm can survive on the yeast. Any worms that significantly 
survived longer than the number of days the N2 worms survived were considered successfully 
mutated and resistant to C. albicans. If a worm is able to survive past this bench mark, it was 
taken off of the yeast plate and placed onto its own E. coli plate and given a strain number. 
After a few days when the strains have a chance to repopulate, 3 or 20 of the L4 stage C. 
elegans were re-plated onto 60 mm X 15 mm plates containing C. albicans, E. coli, and 
streptomycin for a second test. This process ensured that the worms that were thought to have a 
mutation resulting in resistance to C. albicans were not false positives.  
 
3.4.1 Troubleshooting Problems with Overgrown Candida albicans 
There were issues with the overgrowth of C. albicans on the plates. When testing the C. 
elegans, it was difficult to determine if the worms were alive due to the difficulty of seeing the 
worms. This problem was avoided by taking a sample of the yeast mixture from the plate using a 
worm pick and spreading it out on an empty plate. If the worms were motionless even when 
stimulated by the worm pick as illustrated in Figure 13 left image, then that plate can be searched 
for possible survivors. The arrow in the left image indicates a dead worm. However, if most 
worms end up moving around as illustrated in the right image of Figure 13, then the majority of 
the worms are still alive. An indication that they are moving around is a telltale trail that the 
worms leave when moving though the E. coli, as indicated by the arrow in the right image. 
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Figure 13: Troubleshooting Problems with Overgrown Yeast  
Comparing Dead to Live Caenorhabditis elegans (32x) 
The large amounts of yeast on the C. albicans-containing plates can be difficult to work 
with when looking for survivors. However, typically the worms that were alive were found 
moving around on top of the yeast and were visible under the microscope. 
 
3.5 How to Determine if Caenorhabditis elegans are Healthy 
 A worm was considered healthy if it grew to a normal adult size, was able to reproduce, 
and was constantly moving about in its environment. The unhealthy worms were seen as 
scrawny and sluggish moving individuals. The dead worms did not move or respond to 
stimulation by a worm pick. Images of the three different classifications of worms are seen in 
Figure 14 below. 
 
 
Figure 14: Images of Healthy, Unhealthy, and Dead N2 Caenorhabditis elegans Respectively (264x) 
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3.6 Methods for Retesting Candida Resistance 
The retests were performed by taking 3 or 20 of the healthiest looking L4 worms from the 
maintained recovery plates. The worms were counted every few days using a grid system. A lid 
containing 24 drawn out squares, as shown in Figure 15, was placed over the plate and the 
number of worms in one of the squares was counted and then multiplied by 24 to get an estimate 
of the number of healthy worms on the entire plate.  
 
 
Figure 15: Grid Counting System used to Determine Approximate Number of Caenorhabditis elegans 
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4. Results 
4.1 First Survival Screens 
Nine different batches of C. elegans were mutated using either EMS or ENU, allowed to 
recover for 2-3 days on E. coli containing plates, then tested for survival on C. albicans, E .coli, 
and streptomycin-containing media plates. When most of the worms had died and only few 
healthy survivors remained, those survivors were allowed to recover and multiply on NG agar 
plates before retesting to ensure the worms were resistant to the C. albicans. All generations of 
C. elegans were transferred from the recovery plates to the yeast test plates.  
After the first survival test (T1) of the nine mutation batches, survivors were identified, 
isolated, and labeled. Table 1 shows the mutation number along with the mutagen used, number 
of worms tested, and the isolated strains after survival test 1. All of the raw and normalized data 
throughout the results are located in Appendix B. 
Table 1: Candida albicans Survivor Information for Mutated Caenorhabditis elegans in Survival Assay Test 1 
Mutation 
Number 
Mutagen 
Used 
Approximate 
Number of  
C. elegans Tested 
Survivors after Test 1 
1 EMS 3,300 M1S1, M1S2, M1S3, M1S4, M1S5, M1S6, 
M1S7, M1S8 
2 EMS 84,700 M2S1, M2S2, M2S3, M2S4 
3 EMS 40,000 M3S1, M3S2 
4 EMS 62,500 M4S1, M4S2, M4S3, M4S4 
5 EMS 57,600 NONE 
6 ENU 45,000 M6S1, M6S2, M6S3, M6S4, M6S5, M6S6 
7 ENU 61,000 M7S1, M7S2, M7S3, M7S4, M7S5, M7S6, 
M7S7 
8 EMS 31,500 M8S1, M8S2, M8S3, M8S4, M8S5, M8S6, 
M8S7, M8S8 
9 ENU 46,700 M9S1, M9S2, M9S3, M9S4 
 
Using the number of C. elegans that were mutated and screened along with the total 
number of T1 survivors, the percent survival was calculated for each mutagenesis. The average 
percent survival for all mutations is compared to the average for EMS mutations and the average 
for ENU mutations. Standard deviations were also calculated for easy comparison of the 
averages; all this information is shown below in Table 2. 
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Table 2: Average Percent Survival and Standard Deviation of EMS and ENU Mutations Compared to All 
of the Mutations 
Mutagen EMS ENU All Mutations 
Average  Percent 
Survival 
0.0473% 0.0111% 0.0099% 
Standard  
Deviation 
0.0960% 0.0024% 0.0740% 
 
The percent survival for each individual mutagenesis batch is graphed below in Figure 
16, showing the difference in survival rate between mutations. While mutagenesis 1 is a clear 
outlier, the rest of the survival rates are similar. With the exception of mutagenesis 1, all survival 
rates fall within the error bars of the other points. 
 
 
Figure 16: Percent Survival Rates for Each Mutagenesis 
Error bars show 1 Standard Deviation 
 
4.2 Second Survival Screens 
 After the first survival screens, the 43 identified survivors were allowed to recover on E. 
coli plates and multiply before being tested again on C. albicans, E. coli, and streptomycin–
containing media. They were tested for a second time (T2) to ensure that the identified survivors 
were truly resistant mutants to C. albicans. When performing the second survival test, L4 C. 
elegans were selected for retesting and the results are shown in the graphs below. After the 
second survival assay, there were 13 mutant C. elegans strains that stood out as being likely 
resistant mutants. 
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 Worm counts for test 2 were normalized because different T2 tests of different strains 
started with varying numbers of C. elegans. Due to the differences in timing between 
mutagenizing different batches, secondary tests could not be conducted at the same time.  By 
normalizing the data all of the graphs can easily be compared to each other. This was done by 
taking the number of worms that were counted each day and dividing it by the number of worms 
that started out on the plate.  
 The average number of offspring of N2 C. elegans was determined by plating 20 L4 C. 
elegans on C. albicans, E. coli, and streptomycin-containing media. The average number of 
healthy worms, classified by their movement, size, and eventually their ability to grow, was 
counted every few days. The graph showing the survival counts of the N2 worms is illustrated in 
Figure 17 below. The data was normalized by dividing the number of worms counted each day 
by the initial number of worms on the plate.   
 
 
Figure 17: Number of N2 Caenorhabditis elegans on Candida albicans Plates over Time 
The peaking of the number of worms is seen when new worms were born and looked 
healthy before they were starved from the lack of E. coli and the inability to ingest the C. 
albicans. Overall, the infection and dying process of N2 worms on the yeast plates took about 17 
days. 
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Figure 18: Number of Caenorhabditis elegans from Mutation 6 on Candida albicans Plates over Time 
The graph in Figure 18 shows the number of original C. elegans and the offspring that 
remained healthy in mutation batch 6. Out of the six strains collected from test 1 only one strain, 
M6S2, looked to be a probable resistant mutant due to the larger number of worms that remained 
healthy. 
 
 
Figure 19: Number of Caenorhabditis elegans from Mutation 7 on Candida albicans Plates over Time 
The graph in Figure 19  shows the number of original C. elegans and the offspring that 
remained healthy in mutation batch 7. Out of the seven strains collected from test 1 only two 
strains, M7S3 and M7S7, looked to be probable resistant strains.  
0
50
100
150
200
250
0 3 8 11 14
N
um
be
r o
f W
or
m
s 
Number of Days on Yeast Plates 
M6S1
M6S2
M6S3
M6S4
M6S5
M6S6
0
50
100
150
200
250
300
350
0 3 8 11 14
N
um
be
r o
f W
or
m
s 
Number of Days on Yeast Plates 
M7S1
M7S2
M7S3
M7S4
M7S5
M7S6
M7S7
 28 
 
 
Figure 20: Number of Caenorhabditis elegans from Mutation 8 on Candida albicans Plates over Time 
The graph in Figure 20 shows the number of original C. elegans and the offspring that 
remained healthy in mutation batch 8. The results gathered were inconclusive. Therefore, the 
strains were considered survivors were based off of their morphology seen on the plates on the 
last day of testing with the focus on healthy L4 worms. Using this classification, the strains that 
were considered survivors are M8S1, M8S3, M8S5, M8S6, and M8S8. 
 
 
Figure 21: Number of Caenorhabditis elegans from Mutation 9 on Candida albicans Plates over Time 
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The graph in Figure 21  shows the number of original C. elegans and the offspring that 
remained healthy in mutation batch 9. Out of the four strains collected from test 1 only two 
strains, M9S1 and M9S2, looked to be probable resistant mutants. All likely survivor strains after 
test 2 are listed in Table 3 below. 
Table 3: Survivor Information for Mutated Caenorhabditis elegans from Survival Assay Test 2 
Mutation Number Mutagen Used Survivors after Test 2 
1 EMS M1S2, M1S3 
2 EMS NONE 
3 EMS NONE 
4 EMS M4S1 
5 EMS NONE 
6 ENU M6S2 
7 ENU M7S3, M7S7 
8 EMS M8S1, M8S3, M8S5, M8S6, M8S8 
9 ENU M9S1, M9S2 
 
4.3 Third Survival Screen on Three Putative Mutants 
Due to timing, out of the 13 mutant C. elegans strains, only three were able to undergo a 
third survival assay: M1S2, M1S3, and M4S1. These three mutant worms underwent testing 
along with a N2 control. Figure 22 shows the three putative mutants compared to N2 C. elegans. 
The arrows indicate changes in the morphology, specifically the extended or distended lumen. 
These morphological changes were seen in the majority of the worms in that strain.  
 
 
Figure 22: Three Putative Mutants Compared to N2 Caenorhabditis elegans (264x) 
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 The putative mutants that survived the T2 were taken off their respective plates and 
allowed to recover. The number of healthy worms in one grid section for each plate was counted 
every few days, multiplied by the number of grid sections on the plate, normalized for easy 
comparison, and graphed in Figure 23. The graph shows the number of original C. elegans and 
the offspring that remained healthy over time.  
 
 
Figure 23: Number of Caenorhabditis elegans from T3 on Candida albicans Plates over Time 
As the graph illustrates, most of the worm strains reproduced and peaked around day 7 
before starting a steady decline of healthy worms. However, M4S1 continued a steady growth in 
the number of healthy worms on the plates. 
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5. Discussion 
5.1 Mutagenesis of Caenorhabditis elegans 
After mutagenizing C. elegans using either EMS or ENU, the mutants were exposed to C. 
albicans, E. coli, and streptomycin-containing media in multiple survival assays. Both types of 
mutagens created point mutations by switching purine base pairs to pyrimidines or vice versa. 
These mutagens were selected because point mutations are much less likely to be severely 
detrimental to the organism than frame-shift mutations, which causes insertions or deletions of 
nucleotides. This can completely disrupt the transcription of the entire gene by prematurely 
stopping the transcription of the gene or altering the entire amino acid sequence of the protein 
because all the codons after the mutation are disrupted. EMS and ENU induce point mutations 
that change the identity of a single nucleotide that can either alter a single amino acid used when 
translating the gene or alter regulatory protein and RNA binding affinity to the gene. Both 
mutagens will change a base to pair with the opposite type of base – for example nucleotide A 
would be chemically altered to pair with nucleotide G instead of nucleotide T. The DNA 
replication that takes place during cell division would insert a different base opposite the altered 
one. Effectively, an A/T base pair has been changed to a G/C base pair. EMS changes G/C pairs 
to A/T, while ENU does the opposite, changing A/T pairs to G/C using the same mechanism. 
Due to the stress that mutagenesis causes, worms were allowed to recover on E. coli plates after 
mutagenesis before testing on yeast plates. 
Due to the uncertainty of what gene, when mutated, can confer resistance to C. albicans 
infections, mutation was not directed. The overall frequency of mutation for EMS is 3x10-4 per 
gene per genome. We cannot compare this frequency directly to the apparent frequencies we 
obtained because the only relevant counts were the numbers of F1s.  This is because the F1 
generation contains each mutation in a single individual; thus the number of mutant F1s most 
directly reflects the observed mutation frequency.  In our mutagenesis experiments, we tested 
mixed generations of offspring of mutagenized worms, so they were not all from the F1 or F2 
generation. 
 
5.2 First Survival Screens Analysis 
Once the C. elegans were mutated, the primary test was done to serve two purposes. The 
first purpose was to eliminate the non-mutant C. elegans from the mutant ones and this was 
visible when most of the worms were dying at around the same time as the control N2. The 
second purpose was to isolate the mutants that displayed a resistance to the C. albicans. This was 
determined when the worms were alive and healthy on the yeast plates for an extended period of 
time, sometimes greater than one month. This would ensure that the supply of E. coli would be 
completely depleted in a short period of time due to the streptomycin, forcing the worms to rely 
on ingesting the C. albicans. The mutated, non-resistant C. elegans would be eliminated, thereby 
leaving the C. albicans resistant C. elegans for isolation.  
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After survival test 1, 43 resistant mutants were isolated. Some of the survivors selected 
from mutagenesis 1 were not resistant to the yeast infection, contributing to the apparent high 
survival frequency from that mutation batch. The survival frequency of mutation 1 was 
calculated to be 0.2424% and when compared to the survival frequency for the rest of the 
mutations shown in Figure 16, it is the only outlier. However, this data was still included in the 
calculation of the overall percent survival 0.0099%, shown in Table 2. This major difference is 
what caused the large standard deviation of 0.0740% for the overall survival rate and for the 
EMS survival rate.  The reason for this discrepancy is likely that in the first mutagenesis, the 
mutant worms were selected and isolated too soon so they could have been sick worms instead of 
resistant mutant C. elegans. After secondary testing, it was observed that most of the 
mutagenesis 1 survivors were not truly resistant and the duration of the first test was increased 
for future mutation batches. As shown in Figure 16, subsequent mutations 2 through 9 had 
consistent survival rates. 
 
5.3 Second Survival Screens Analysis 
There were several reasons why a strain selected after test 1 may not be a resistant 
mutant. Young worms are too small to ingest the C. albicans, and therefore can be in the 
presence of the yeast without being infected. A mutant may not have ingested a significant 
amount of yeast on the first test plate, thereby allowing it to survive even though it was not 
resistant to the infection in the first place. Additionally, a worm that was infected and had not 
begun to show significant symptoms could have been selected as a survivor. A worm could also 
be slightly resistant to the infection, allowing it to survive longer than the others but not enabling 
it to endure prolonged exposure to the C. albicans. Some mutations may confer resistance but 
also inhibit other functions. Therefore, secondary tests were performed to ensure that the worms 
were resistant to the C. albicans and could survive and reproduce in the presence of yeast for an 
extended period of time. After test 1, the 43 initial survivors were allowed to recover on NG agar 
plates before secondary testing.   
The basis of how putative mutant worms were selected from the second survival assay to 
be further deemed as potentially having resistant genes to the yeast was based on the number of 
healthy worms on the plates. The health of the C. elegans was based on their movement and 
stage of life. After a certain number of days, if the C. elegans are at the L4 or higher life stage, 
has good movement that is comparable to N2, appears healthy, and is fairly thick in diameter the 
worms are deemed as further possible candidates that may possess a C. albicans resistant gene. 
However, in mutagenesis 7, shown in Figure 19, there were two C. elegans that seemed to be 
good mutants: M7S3 and M7S7. Because the yeast plates still contained a lot of E. coli, these 
worms may not truly be mutants and will require further testing. The large amounts of E. coli 
potentially allowed the worms to live longer on the plates and to avoid contact with C. albicans. 
For mutagenesis 8, shown in Figure 20, the numerical data were inconclusive, so the strains that 
were selected as putative mutants were based on their morphology and behavior. After secondary 
testing, only 13 of the 43 original mutants survived. These mutants were allowed to recover 
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before a third and final test. As a note, mutation batches 1-5 were not graphed due to the lack of 
data. For strains that appeared to be dying early in the test, the number of worms on the plates 
was not recorded. 
 
5.4 Third Survival Screens on Three Putative Mutants Analysis 
Due to time constraints, at one point in the testing only three mutant strains survived test 
2 and were able to be tested a third time. The three putative mutants and N2 worms were plated 
on yeast plates at the same time and were counted every few days. Figure 23 shows that N2 
control along with M1S2 and M1S3 reproduced and their progeny numbers reached a peak 
around day 7 before steadily declining afterwards. However, the total number of worms on the 
M4S1 plate steadily increased over the 17 days of testing, ending with a total of over 4,000 
worms. The other two mutants were under 1,000 and the N2 control had a total of 192 living 
worms after 17 days of yeast exposure. Therefore, the M4S1 mutant was identified as the mutant 
with the greatest ability to reproduce in the presence of yeast. Upon examining the photos in 
Figure 22 comparing the three mutants to a N2 worm, the morphological symptoms of infection 
are more evident in the M1S2 and M1S3 mutants than in the M4S1. C. elegans infected with C. 
albicans often exhibit an enlarged intestinal lumen, indicated by swelling throughout the center 
of the worm. While the M1S2 and M1S3 mutants have this characteristic swelling of the 
infection, the M4S1 mutant does not show this symptom. In fact, it more closely resembles the 
N2 worm shown in Figure 22 than the other two mutants. This lack of swelling combined with 
its superior survival numbers indicates that the M4S1 mutant has a strong resistance to infection 
and is decidedly the best mutant from all three of the putative mutants that underwent test 3. For 
mutant M4S1, there was no data analysis for the second survival test because the data collected 
was lost. However, the mutant strain was still tested on three survival assays and the data 
collected for the third screening was still significant in considering the yeast infection resistant 
ability of the mutant strain. 
 
5.5 Conclusion 
The goal of this research was to isolate mutant strains of C. elegans that may contain a 
mutation that confers resistance against C. albicans infection. The generation of the C. elegans 
progeny was disregarded for the second and third assays since the C. elegans are hermaphrodites 
and each progeny has a genetically identical genome as the parent worm. Instead, the main 
consideration was ensuring that the initial C. elegans plated for test 2 and test 3 were L4 or 
higher life stages where they are able to reproduce and ingest and be infected by C. albicans.  
After performing three rounds of tests on over 432,300 C. elegans, 13 different resistant 
strains were isolated. Out of those 13 mutants, specifically the three that underwent test 3, one 
particular mutant, M4S1, was considered the most probable resistant mutant strain due to its lack 
of physical symptoms of infection and high survival rates. 
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5.6 Recommendations and Future Applications 
For future research on determining more possible mutant C. elegans that can confer 
resistance to C. albicans, liquid media could be used that will convert the yeast into it hyphal 
form. By using this form of the yeast, a more accurate study can be done in C. elegans that is 
more reflective of the physiological and morphological changes that occur in systemic patients. 
We further suggest that more testing be performed on the remaining strains that survived 
test 2 to ensure resistance and to identify the most probable resistant mutant strains.  These tests 
should be true survival tests in which survival of the original L4 worms put on the test plate is 
distinguished from their reproduction, and the growth of their offspring. 
 Subsequently through complementation tests and genome sequencing, the specific 
mutation that confers resistance can be identified. The identification of the mutated gene will 
show where and possibly how C. albicans normally affects C. elegans. Moving forward from 
this point, the function of the gene related to the resistance can be investigated and similar genes 
in other organisms, eventually humans, could be identified. The knowledge gained from this and 
other studies can potentially lead to the development of a drug to treat systemic Candidiasis.  
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Appendix A: Recipes and Specifics for Materials and Methods 
 
NG Agar Plates 
Materials: 
• 1L glass bottle  
• Stir Bar & Plate 
• 1000 mL graduated cylinder  
• Repeating pipettor 
• Aluminum foil 
• Autoclave tape 
• Sterile 1 mL pipettes 
• Sterile 25 mL pipettes 
• Pipetman 
 
Chemicals: 
• 3.0 g NaCl 
• 2.5 g Peptone 
• 17.0 g Agar 
• Sterile 1 mL 1M CaCl2 
• Sterile 1M MgSO4 
• Sterile 25 mL 1M KPO4 
• Sterile 1 mL 0.5% cholesterol 
 
Procedure: 
1. Fill 1L glass bottle with 500 mL of dH2O  
2. Add a stir bar and then the NaCl and peptone 
3. Pour the solution back into the graduated cylinder and add more dH2O until the 
975 mL mark is reached  
a. Note: ensure not to measure with the stir bar in the graduated cylinder 
4. Pour solution back into the glass bottle  
5. Add agar and mix well 
6. Autoclave the mixture and the repeating pipettor that is wrapped in aluminum foil 
for 15 minutes at 121°C 
a. Note: Be sure to leave the stir bar in the bottle while autoclaving 
b. Note: When placing the autoclave tape on to the bottle, loosen the tops of 
the bottle to prevent explosions 
7. Cool mixture down to 50°C and aseptically add the remaining chemicals 
8. Using the repeating pipettor, 10 mL of the solution was dispensed into 60 mm X 
15 mm Petri dishes 
9. Rinse bottle and repeat pipettor with hot water 
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Yeast Peptone Dextrose (YPD) Agar Plates  
Materials: 
• 1L glass bottle 
• Stir Bar & Plate 
• 1000 mL graduated cylinder  
• Sterile 30 mL pipet 
• Pipetman 
• Autoclave tape
 
Chemicals: 
• 10.0 g Yeast extract 
• 20.0 g Peptone 
• 20.0 g Dextrose 
• 15.0 g Agar
 
Procedure: 
1. Fill 1L glass bottle with 1L of dH2O  
2. Add a stir bar and then all of the ingredients 
3. Autoclave the mixture for 15 minutes at 121°C 
a. Note: Be sure to leave the stir bar in the bottle while autoclaving 
b. Note: When placing the autoclave tape on to the bottle, loosen the tops of 
the bottle to prevent explosions  
4. When the solution is cooled down, dispense 30 mL of the solution into 90 mm 
Petri dishes using the pipet and the pipetman 
5. Rinse bottle with hot water 
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LB Media 
Materials: 
• 500 mL glass bottle 
• 100 mL glass bottles 
• Stir Bar & Plate 
 
Chemicals: 
• 2.0 g Tryptone 
• 1.0 g Yeast extract 
• 1.0 g NaCl 
• Sterile 80 µL 5N NaOH 
 
Procedure: 
1. Add 150 mL dH2O and all the ingredients to 500 mL glass bottle and stir until 
dissolved 
2. Bring up to a final volume of 200 mL and dispense 50 mL into 100 mL glass 
bottles 
3. Autoclave immediately 
 
YPD Media 
Materials: 
• 1L glass bottle 
• 100 mL glass bottles 
• Stir Bar & Plate 
• 1000 mL graduated cylinder  
Chemicals: 
• 10.0 g Yeast extract 
• 20.0 g Peptone 
• 20.0 g Dextrose 
 
Procedure: 
1. Add 1000 mL dH2O and all the ingredients to 1L glass bottle and stir until 
dissolved 
2. Dispense 50 mL into 100 mL glass bottles 
3. Autoclave immediately 
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OP50 E. coli Spotting and Streaking 
Materials: 
• OP50 E. coli streaked plate 
• Sterile metal loop 
• NG agar plates 
• Pipette bulb 
• Bunsen burner 
• Sterile Pasteur pipette 
• LB agar plates 
• Parafilm 
 
Chemicals: 
• Sterile 50 mL LB media 
Procedure: 
1. Aseptically removed one colony from an OP50 E. coli streaked plate and place in a 
bottle containing 50 mL LB media whose bottle opening was flamed 
2. Place the bottle into a shaker incubator overnight at 37°C to allow the bacteria to 
grow 
3. After 24 hours, 2-3 drops of the liquid E. coli solution was placed into each of the N2 
agar plates using a sterile Pasteur pipette 
4. To maintain a fresh stock of OP50 E. coli, a new LB agar plate was streaked by 
removing a single colony from the old OP50 E. coli streaked plate with a flamed loop 
and zig-zagged over an area of the plate at room temperature for isolation 
5. The zig-zagged plate was placed into a 37°C incubator overnight to allow a lawn to 
grow before it was removed and parafilmed for storage 
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Candida albicans Streaking and Spotting with OP50 E. coli and Streptomycin 
Materials: 
• Candida albicans streaked plate 
• E. coli streaked plate 
• Sterile metal loop 
• YPD agar plates 
• Sterile conical tubes 
• Bunsen burner 
• Sterile Pasteur pipette 
• Pipette bulb 
• Parafilm
 
Chemicals: 
• Sterile 50 mL YPD media 
• Sterile 50 mg/mL Streptomycin 
• Sterile 50 mL LB media 
• Sterile M9 solution 
 
Procedure: 
1. Aseptically removed one colony from a Candida albicans streaked plate and place it 
in a bottle containing 50 mL YPD media whose bottle opening was flamed 
2. Aseptically removed one colony from an E. coli streaked plate and place it in a bottle 
containing 50 mL LB media whose bottle opening was flamed 
3. Place both bottles into a shaker incubator overnight at 37°C to allow the yeast and the 
bacteria to grow 
4. After 24 hours, the inoculated media was removed from the incubator and 1 mL of 
the yeast solution was placed into a sterile conical tube 
5. 9 mL M9 was then added to the conical tube to perform a 1:10 dilution and the 
mixture mixed 
6. Afterwards, 3.3 mL E. coli inoculated LB media and 13.3 mL streptomycin was 
placed into the conical tube and the solution mixed 
7. 3-5 drops of the liquid mixture was dropped onto the center of each YPD agar plates 
8. To maintain a fresh stock of Candida albicans, a new YPD plate was streaked by 
removing a single colony from the old Candida albicans streaked plate with a flamed 
loop and zig-zagged over an area of the plate at room temperature for isolation 
9. The zig-zagged plate was placed into a 37°C incubator overnight to allow a lawn to 
grow before it was removed and parafilmed for storage 
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1M CaCl2, 500mL 
73.5 g CaCl2 · 2H2O 
Add 450 mL dH2O to CaCl2 and stir until dissolved. Bring up to a final volume of 500 mL. 
Autoclave. 
 
1M KPO4 Buffer 1L 
108.3 g KH2PO4 (monobasic, anhydrous) 
35.6 g K2HPO4 (dibasic, anhydrous) 
Add 800 mL dH2O, pH to 6, and then bring to 1L. Autoclave. 
 
1M MgSO4, 500mL 
123.2 g MgSO4 · 7H2O 
Add 450 mL dH2O to MgSO4 and stir until dissolved. Bring up to a final volume of 500 mL. 
Autoclave. 
 
M9 Salt 
10.5 g Na2HPO4 · 7H2O 
3.0 g KH2PO4 
0.5 g NaCl 
1.0 g NH4Cl 
Add 800 mL dH2O, pH to 7.2, and then bring to 1L. Autoclave. 
 
0.5% Cholesterol in Ethanol 
2.5 g cholesterol in 500 mL ethanol 
Stir until dissolved and filter sterilize. Do not autoclave. 
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Caenorhabditis elegans Mutagenesis 
Materials: 
• At least 5 plates of ~300 L4 worms on each plate 
• Glass Pipettes and Bulb 
• Sterile 2 15 mL conical 
• Sterile 50 mL conical 
Chemicals: 
• Sterile M9 Solution 
• 20 µL 50 mM EMS or ENU solution 
• NaOH Pellets 
Procedure: 
1. Fill 50 mL conical with NaOH pellets to the 5 mL mark, any item or liquid that 
comes in contact with EMS must be placed into this container and discarded 4 days 
later 
a. This is only for EMS, for ENU, the chemical will degrade at room 
temperature over 24 hours.  
2. Wash worms off of media plates with M9 and place in 15 mL conical tube 
3. Centrifuge tubes at 2,000 RCF (3,000 rpm) for 1 minute, remove supernatant and 
rinse with M9, repeat centrifuge process 
4. Remove supernatant and bring total volume up to 2mL 
5. Add either the EMS or ENU mutagenic, making the final concentration 25 mM in a 
total volume of 4 mL 
a. 𝐶1𝑉1 = 𝐶2𝑉2 (2𝑚𝐿)𝑥(50𝑚𝑀) = (4𝑚𝐿)𝑥(𝑋)  𝑋 = 25𝑚𝑀 
6. Allow to rotate on a nutator for 4 hours at 20ºC 
7. After 4 hours centrifuge down the sample, remove the supernatant and rinse with M9, 
repeat this step 3-4 times 
a. Ensure to dispose of any materials or liquids that could possibly contain the 
chemicals correctly 
8. Once rinsed correctly, plate onto white plates containing E. coli and place in 22ºC 
incubator  
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Appendix B: Results Data 
 
Table B 1: Number of Caenorhabditis elegans Tested and Number of Survivors and Survival Rate for 
Each Mutagenesis 
Mutation 
Number 
Mutagen 
Used 
Approximate 
Number of 
Worms 
Tested 
Number of 
Survivors 
Percent 
Survivors 
1 EMS 3300 8 0.2424% 
2 EMS 84700 4 0.0047% 
3 EMS 40000 2 0.0050% 
4 EMS 62500 4 0.0064% 
5 EMS 57600 0 0.0000% 
6 ENU 45000 6 0.0133% 
7 ENU 61000 7 0.0115% 
8 EMS 31500 8 0.0254% 
9 ENU 46700 4 0.0086% 
Total  432300 43 0.0099% 
 
Table B 2: Raw Data for Number of Wild Type N2 Caenorhabditis elegans  
on Candida albicans Plates over Time 
Plate Name Number of 
Worms:  
Day 0 
Number of 
Worms:  
Day 3 
Number of 
Worms:  
Day 7 
Number of 
Worms:  
Day 14 
Number of 
Worms: 
Day 17 
N2 T1-1 20 3024 6000 312 192 
N2 T1-2 20 3120 5928 240 72 
 
Table B 3: Averaged and Normalized Data for Number of Wild Type N2 Caenorhabditis elegans on 
Candida albicans Plates over Time 
Strain 0 3 7 14 17 
N2 Control 1 153.6 372 13.2 6.6 
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Table B 4: Raw Data for Number of Caenorhabditis elegans from each Strain for T2 of Mutations 6-9 on 
Candida albicans Plates over Time 
Strain Day 0 Day 3 Day 8 Day 11 Day 14 
M6S1 3 3 80 30 30 
M6S2 3 10 400 600 500 
M6S3 3 3 0 0 0 
M6S4 3 3 30 40 60 
M6S5 3 3 3 3 10 
M6S6 3 3 0 0 0 
M7S1 3 3 0 0 0 
M7S2 3 3 1 1 0 
M7S3 3 10 1000 800 200 
M7S4 3 3 0 0 0 
M7S5 3 3 10 20 10 
M7S6 3 3 50 30 15 
M7S7 3 10 400 400 350 
M8S1 3 40 800 1000 300 
M8S2 3 20 2000 200 300 
M8S3 3 35 600 1000 200 
M8S4 3 30 200 150 500 
M8S5 3 35 600 600 500 
M8S6 3 10 200 3000 250 
M8S7 3 30 2000 500 400 
M8S8 3 3 100 100 150 
M9S1 3 3 500 600 600 
M9S2 3 3 200 500 400 
M9S3 3 30 500 3000 20 
M9S4 3 1 1 1 1 
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Table B 5: Normalized Data for Number of Caenorhabditis elegans from Each Strain for T2 of Mutations 
6-9 on Containing Candida albicans Plates over Time 
Strain 0 3 8 11 14 
M6S1 1.00 1.00 26.67 10.00 10.00 
M6S2 1.00 3.33 133.33 200.00 166.67 
M6S3 1.00 1.00 0.00 0.00 0.00 
M6S4 1.00 1.00 10.00 13.33 20.00 
M6S5 1.00 1.00 1.00 1.00 3.33 
M6S6 1.00 1.00 0.00 0.00 0.00 
M7S1 1.00 1.00 0.00 0.00 0.00 
M7S2 1.00 1.00 0.33 0.33 0.00 
M7S3 1.00 3.33 333.33 266.67 66.67 
M7S4 1.00 1.00 0.00 0.00 0.00 
M7S5 1.00 1.00 3.33 6.67 3.33 
M7S6 1.00 1.00 16.67 10.00 5.00 
M7S7 1.00 3.33 133.33 133.33 116.67 
M8S1 1.00 13.33 266.67 333.33 100.00 
M8S2 1.00 6.67 666.67 66.67 100.00 
M8S3 1.00 11.67 200.00 333.33 66.67 
M8S4 1.00 10.00 66.67 50.00 166.67 
M8S5 1.00 11.67 200.00 200.00 166.67 
M8S6 1.00 3.33 66.67 1000.00 83.33 
M8S7 1.00 10.00 666.67 166.67 133.33 
M8S8 1.00 1.00 33.33 33.33 50.00 
M9S1 1.00 1.00 166.67 200.00 200.00 
M9S2 1.00 1.00 66.67 166.67 133.33 
M9S3 1.00 10.00 166.67 1000.00 6.67 
M9S4 1.00 0.33 0.33 0.33 0.33 
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Table B 6: Raw Data for Number of Caenorhabditis elegans from Each Strain for T3 of Three Putative 
Strain on Candida albicans Plates over Time 
Plate Name Number of 
Worms: 
Day 0 
Number of 
Worms: 
Day 3 
Number of 
Worms: 
Day 7 
Number of 
Worms: 
Day 14 
Number of 
Worms: 
Day 17 
M1S2 T3-1 20 3000 4800 480 480 
M1S2 T3-2 20 3552 5280 240 432 
M1S3 T3-1 18 96 6000 1296 960 
M4S1 T3-1 20 2832 3600 2400 3000 
M4S1 T3-2 20 1512 2400 3600 2664 
 
Table B 7: Averaged and Normalized Data for Number of Caenorhabditis elegans from each Strain for T3 
of Three Putative Strain on Candida albicans Plates over Time 
 0 3 7 14 17 
M1S3 1 163.2 252 18 22.5 
M1S3 1 5.33333333 333.333333 78.6666667 53.3333333 
M4S1 1 108.6 150 210 216 
 
